trial

Once Weekly D-cycloserine for Schizophrenia

NCTId NCT00964041
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Withdrawn
Enrollment 0 (actual)
Sponsored by Massachusetts General Hospital
Primary completion 2011-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2009-07
Primary completion
2011-06
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
d-cycloserine

Sponsors

Massachusetts General HospitalLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Donald C. Goff, M.D.Principal Investigator

Sites

1 total
Boston, United States

Facts & assertions

4 sourced
Enrollment
0
Phase
PHASE4
Primary Completion Date
2011-06
Status
WITHDRAWN
relationships
The graph out of here
drug
d-cycloserine
drug
lead_sponsor
Massachusetts General Hospital
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Psychotic Disorders
indication
Cognitive Dysfunction
indication
investigator
Donald C. Goff, M.D.
person